Reprint

New Insights into Endometrial Cancer 2022

Edited by
June 2023
178 pages
  • ISBN978-3-0365-7915-3 (Hardback)
  • ISBN978-3-0365-7914-6 (PDF)

This is a Reprint of the Special Issue New Insights into Endometrial Cancer 2022 that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

This open access Special Issue brings together original research and review articles on molecular oncology, with attention given to endometrial cancer. It highlights new findings, methods, and technical advances in molecular cancer research. The main feature of this Special Issue is that it is a platform for open-source sharing of significant works in the field of molecular oncology that can increase our understanding of endometrial cancer development, which may lead to the discovery of new molecular diagnostic technologies and targeted therapeutics.Topics include:Molecular methods to personalize endometrial cancer screening and detection;Identification and new aspects of cellular signaling molecules and pathways for target discovery, drug design, and personalized and gender medicine;DDI discovery in endometrial cancer management;Drug repurposing for endometrial cancer prevention/treatment;Molecular modeling studies.

Format
  • Hardback
License and Copyright
© 2022 by the authors; CC BY-NC-ND license
Keywords
endometrial cancer; TET proteins; O-GlcNAc transferase; TWIST1; ZEB1; FOXC1; migration; invasion; lipotoxicity; palmitate; endometrial cancer; adjuvant chemotherapy; endometrial cancer; mass spectrometry; serum proteome; Suprabasin; 2D-DIGE; Western blotting; endometrial cancer; lymph node; metastasis; epithelial-to-mesenchymal transition; leave one out cross validation; mass spectrometry; signaling pathways; endometrial cancer; uterine neoplasm; cancer of the endometrium; spectroscopy; Raman spectroscopy; Fourier transform infrared spectroscopy; diagnosis; screening; endometrial cancer; racial disparity; molecular profiling; proteomic; TCGA; endometrial carcinoma; mismatch-repair; p53; molecular; prognosis; treatment; histotype; POLE; microsatellite; endometrial carcinoma; diagnostic markers; prognostic gene; protein–ligand interactions; NRAS gene; endometrial cancer; hypoxia; tumor microenvironment (TME); prognosis; risk model; immune cells; chemotherapy; targeted treatment; endometrial cancer; EphA2; Wee1; n/a